信邦制药
(002390)
| 流通市值：75.76亿 | | | 总市值：76.39亿 |
| 流通股本：19.28亿 | | | 总股本：19.44亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,266,285,288.11 | 2,845,025,271.68 | 1,441,207,780.35 | 6,032,262,052.57 |
| 营业收入 | 4,266,285,288.11 | 2,845,025,271.68 | 1,441,207,780.35 | 6,032,262,052.57 |
| 二、营业总成本 | 4,026,405,575.21 | 2,680,024,975.74 | 1,378,738,264.35 | 5,712,473,384.68 |
| 营业成本 | 3,522,175,511.29 | 2,353,105,700.26 | 1,209,422,451.4 | 4,996,367,504.59 |
| 税金及附加 | 32,382,910.15 | 12,261,893.22 | 6,857,481.57 | 25,012,693.95 |
| 销售费用 | 196,038,993.09 | 129,798,373.69 | 66,084,428.65 | 305,691,534.82 |
| 管理费用 | 260,409,452.14 | 175,086,198.95 | 91,663,427.16 | 364,211,686.05 |
| 研发费用 | 4,292,649.11 | 3,009,434.24 | 709,842.91 | 4,586,715.51 |
| 财务费用 | 11,106,059.43 | 6,763,375.38 | 4,000,632.66 | 16,603,249.76 |
| 其中:利息费用 | 16,204,898.27 | 10,446,340.67 | 5,788,226.69 | 23,538,286.46 |
| 其中:利息收入 | 5,703,181.91 | 4,104,673.61 | 2,002,690.72 | 7,835,746.67 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 266,213.34 | 304,964.14 | 101,384.14 | 2,926,543.94 |
| 资产处置收益 | 85,864.27 | 95,696.33 | 41,126.11 | -2,291,981.97 |
| 资产减值损失(新) | - | - | - | -3,985,503.75 |
| 信用减值损失(新) | -8,110,037.85 | -6,287,040.22 | -1,582,518.96 | -67,628,076.48 |
| 其他收益 | 3,280,069.18 | 1,873,913.39 | 736,396.73 | 6,037,827.9 |
| 四、营业利润 | 235,401,821.84 | 160,987,829.58 | 61,765,904.02 | 254,847,477.53 |
| 加:营业外收入 | 1,337,418.29 | 368,044.83 | 249,870.78 | 13,100,866.38 |
| 减:营业外支出 | 11,511,838.22 | 2,095,788.7 | 921,303.62 | 82,446,846.67 |
| 五、利润总额 | 225,227,401.91 | 159,260,085.71 | 61,094,471.18 | 185,501,497.24 |
| 减:所得税费用 | 24,450,229.75 | 16,814,749.75 | 7,233,429.38 | 29,811,440.25 |
| 六、净利润 | 200,777,172.16 | 142,445,335.96 | 53,861,041.8 | 155,690,056.99 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 200,777,172.16 | 142,445,335.96 | 53,861,041.8 | 155,681,230.01 |
| 终止经营净利润 | - | - | - | 8,826.98 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 152,324,953 | 107,196,832.89 | 41,244,211.17 | 101,381,622.75 |
| 少数股东损益 | 48,452,219.16 | 35,248,503.07 | 12,616,830.63 | 54,308,434.24 |
| 扣除非经常损益后的净利润 | 156,845,693.05 | 106,629,463.12 | 41,075,434.6 | 165,318,585.59 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.08 | 0.06 | 0.02 | 0.05 |
| (二)稀释每股收益 | 0.08 | 0.06 | 0.02 | 0.05 |
| 九、综合收益总额 | 200,777,172.16 | 142,445,335.96 | 53,861,041.8 | 155,690,056.99 |
| 归属于母公司股东的综合收益总额 | 152,324,953 | 107,196,832.89 | 41,244,211.17 | 101,381,622.75 |
| 归属于少数股东的综合收益总额 | 48,452,219.16 | 35,248,503.07 | 12,616,830.63 | 54,308,434.24 |
| 公告日期 | 2025-10-29 | 2025-08-30 | 2025-04-30 | 2025-04-15 |
| 审计意见(境内) | | | | 标准无保留意见 |